11th ECA Webinar: SGLT2 inhibitors in type 1 diabetes @EASDiabetes

Uploaded May 2025 | Updated September 2026, 3 days ago

Prof. Markus Laimer from the University Hospital Bern in Switzerland reviews current evidence on the metabolic effects of SGLT2 inhibitors in type 1 diabetes, highlights remaining knowledge gaps, and explores future directions for their use in treatment. He evaluates the risk of diabetic ketoacidosis when using SGLT 2 inhibitors in people living with type 1 diabetes and explains why he still considers them a beneficial treatment option in well-controlled and educated patient groups.
#diabetes #type1diabetes #diabetestreatment #diabetescare

11th ECA Webinar: SGLT2 inhibitors in type 1 diabetes

#EASD2022 Interview with Stefan Bornstein on the issue of Long COVID and diabetes

#EASD2022 Interview with Rury Holman and Amanda Adler on the UKPDS 44 Year Follow-up

Best of EASD 2025 by the EASD Early Career Academy - featuring Dr. Lorenzo Nesti

EASD 2025: What if Insulin Resistance Could be Treated like Hypertension or High Cholesterol?

EASD 2023 - EASD/ADA consensus report on hyperglycaemic crises in adult patients with diabetes

EASD 2023 - Peter Thorn and Sushil Rane explaining the relationship between diabetes and the brain

EASD 2025: Results from the SOUL Trial - The Cardiologists Perspective

Meet the EASD Early Career Academy - Introducing Pierre Larraufie

#EASD2022 Interview with the EASD-Lilly Centennial Anniversary Prize Lecturerer Matthias Tschöp

9th ECA Webinar: How to DiRECT understanding of t2d into a major advance in clinical care

EASD 2023 - What is the Hypo-RESOLVE project?